KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Treasury Shares: 2021-2025

Historic Treasury Shares for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $30.6 million.

  • Recursion Pharmaceuticals' Treasury Shares rose 69.35% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year increase of 69.35%. This contributed to the annual value of $27.3 million for FY2024, which is 79.35% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Treasury Shares stood at $30.6 million for Q3 2025, which was up 41.36% from $21.7 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Treasury Shares registered a high of $30.6 million during Q3 2025, and its lowest value of $76,762 during Q2 2021.
  • Its 3-year average for Treasury Shares is $19.9 million, with a median of $18.5 million in 2023.
  • Data for Recursion Pharmaceuticals' Treasury Shares shows a peak YoY soared of 9,055.72% (in 2022) over the last 5 years.
  • Recursion Pharmaceuticals' Treasury Shares (Quarterly) stood at $478,136 in 2021, then soared by 1,341.96% to $6.9 million in 2022, then spiked by 120.81% to $15.2 million in 2023, then spiked by 79.35% to $27.3 million in 2024, then skyrocketed by 69.35% to $30.6 million in 2025.
  • Its last three reported values are $30.6 million in Q3 2025, $21.7 million for Q2 2025, and $26.2 million during Q1 2025.